Clinical trial readout dates for Oruka Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is October 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2 ORKA-001 Plaque Psoriasis · NCT07290569 | October 2026 Primary data collected |
| Phase 2 ORKA-002 Plaque Psoriasis · NCT07474792 | October 2027 Ongoing |
| Phase 2 ORKA-002 Hidradenitis Suppurativa (HS) · NCT07783542 | October 2028 Recruiting |
| Phase 2 ORKA-002 Plaque Psoriasis · NCT07933783 | July 2029 Enrolling |
| Phase 2 ORKA-001 Plaque Psoriasis · NCT07449702 | May 2030 Recruiting |
Oruka Therapeutics Inc. reported $1.21B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $50M; at that rate the cash would last about 24 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Other Events — often topline trial data | 2026-10-26 |